Company news

Arovella Therapeutics Limited news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Arovella Completes $12.5M Placement - Funded to Phase 1 Data

March 25, 2024

Pause in Trading

March 21, 2024

Appendix 4D and Half Year Report

February 28, 2024

Arovella licenses novel CAR-iNKT cell armouring technology

January 29, 2024

Arovella receives R&D tax credit of $1.94 million

November 20, 2023

Arovella licenses novel solid tumour targeting technology

October 11, 2023

Reinstatement to Quotation

October 11, 2023

Suspension from Quotation

October 11, 2023

Response to ASX Price Query

August 30, 2023

Quarterly Appendix 4C and Activities Report

July 24, 2023

Completion of oversubscribed Share Purchase Plan (SPP)

July 10, 2023

Share Purchase Plan (SPP) Closing Date Extended

June 28, 2023

Share Purchase Plan (SPP) Offer Booklet

June 14, 2023

Arovella completes $4M placement & launches $1M SPP

June 7, 2023

Arovellas OroMist R&D facility closure completed

May 1, 2023

Response to ASX Query

April 26, 2023

Response to ASX Aware Query

April 20, 2023

ALA-101 confers survival benefit in leukemia model

April 16, 2023

Arovella completes $1.65M placement

January 18, 2023

R&D Tax Incentive refund received

November 29, 2022

Europe Patent granted for iNKT Cell Therapy Platform

November 6, 2022

Arovella to close its Perth OroMist R&D Facility

October 25, 2022

Preclinical trial of ALA iNKT therapy and IMU onCARlytics

September 26, 2022

Preliminary Final Report

August 31, 2022

Quarterly Appendix 4C and Activities Report

July 28, 2022

Sumatriptan Update

June 27, 2022

ZolpiMist Launch Australia

June 22, 2022

Adopts WEF Framework For ESG Reporting

June 7, 2022

Services Agreement with Q-Gen for CAR19-iNKT manufacture

April 20, 2022

Anagrelide patent for the United States

April 5, 2022

Arovella Therapeutics: Proposed issue of securities - ALA

March 17, 2022

Application for quotation of securities - ALA

March 16, 2022

Update - Proposed issue of securities - ALA

February 28, 2022

Arovella SPP Closed early over subscribed

February 21, 2022

Investor Presentation

January 31, 2022

SPP Offer Booklet

January 23, 2022

Arovella Completes $4.57M Placement & Launches $1.5M SPP

January 23, 2022

AGM FY21 Presentation

December 15, 2021

Arovella licences novel monoclonal antibody from MD Anderson

December 12, 2021

Chile Ministry of Health Approval Granted for ZolpiMist

October 20, 2021

GM presentation

October 13, 2021

Dr Reuben Benjamin Appointed to SUDA iNKT Cell Therapy SAB

August 25, 2021

SUDA signs Licence and Distribution Agreement with STADA

August 24, 2021

ZolpiMist Update

August 23, 2021

iNKT cell therapy platform update

August 16, 2021

SUDA appoints new cell and gene therapy manufacturing expert

August 1, 2021

Disclosure Document Prospectus $3.65m

June 22, 2021

SUDA Placement Raises $3.65m

June 22, 2021

Investor Presentation incorporating iNKT Cell Platform

June 18, 2021

SUDA Licenses a Novel iNKT Cell Therapy Platform

June 18, 2021

← Newer news releases · Older news releases →

Decks

The 5 newest of 45 decks. Every deck is listed under its year.